← back to search

Rachel O’Connell

Royal Marsden NHS Foundation Trust · GB
Area of research
Surgery · Cancer Research
Research interest
Research interests include Breast Cancer Treatment Studies, Breast Implant and Reconstruction, Ovarian cancer diagnosis and treatment, and Reconstructive Surgery and Microvascular Techniques.
h-index
29
citations
5,315
works
210
NIH funding
primary concept
Medicine
email

Recent publications

The effect of monthly vitamin D supplementation on fractures: a tertiary outcome from the population-based, double-blind, randomised, placebo-controlled D-Health trial
The Lancet Diabetes & Endocrinology 2023cited by 33position: middledoi
Mastitis and Mammary Abscess Management Audit (MAMMA) in the UK and Ireland
British journal of surgery 2023cited by 6position: middledoi
The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality
The Lancet Diabetes & Endocrinology 2022cited by 166position: middledoi
Multi-centre randomised controlled trial comparing arthroscopic hip surgery to physiotherapist-led care for femoroacetabular impingement (FAI) syndrome on hip cartilage metabolism: the Australian FASHIoN trial
BMC Musculoskeletal Disorders 2021cited by 66position: middledoi
The effect of vitamin D supplementation on acute respiratory tract infection in older Australian adults: an analysis of data from the D-Health Trial
The Lancet Diabetes & Endocrinology 2021cited by 64position: middledoi
Vitamin D supplementation and risk of falling: outcomes from the randomized, placebo‐controlled D‐Health Trial
Journal of Cachexia Sarcopenia and Muscle 2021cited by 63position: middledoi
Efficacy of a Combination of Conservative Therapies vs an Education Comparator on Clinical Outcomes in Thumb Base Osteoarthritis
JAMA Internal Medicine 2021cited by 42position: middledoi
Innovations for the future of breast surgery
British journal of surgery 2021cited by 21position: middledoi
Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study
The Journal of Clinical Endocrinology & Metabolism 2020cited by 67position: middledoi
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors
Gynecologic Oncology 2019cited by 88position: middledoi
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903
Gynecologic Oncology 2019cited by 59position: middledoi
TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG
Annals of Surgical Oncology 2017cited by 240position: middledoi
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
Quality of Life Research 2017cited by 58position: middledoi
The D-Health Trial: A randomized trial of vitamin D for prevention of mortality and cancer
Contemporary Clinical Trials 2016cited by 112position: middledoi
Detection of Primary Melanoma in Individuals at Extreme High Risk
JAMA Dermatology 2014cited by 141position: middledoi
The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study
Diabetologia 2014cited by 92position: middledoi
Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales
British Journal of Cancer 2014cited by 82position: middledoi
HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes
Diabetes Care 2014cited by 71position: middledoi
Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Diabetologia 2013cited by 68position: middledoi
Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes
The Journal of Clinical Endocrinology & Metabolism 2012cited by 83position: middledoi
The Index of Microcirculatory Resistance Predicts Myocardial Infarction Related to Percutaneous Coronary Intervention
Circulation Cardiovascular Interventions 2012cited by 78position: middledoi
Rates and predictors of risk of stroke and its subtypes in diabetes: a prospective observational study
Journal of Neurology Neurosurgery & Psychiatry 2012cited by 64position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Anthony Keech · Medical Research Foundation7 papers (2012–2020)David C. Whiteman · University of Edinburgh5 papers (2016–2023)Bruce K. Armstrong · UNM Comprehensive Cancer Center5 papers (2016–2023)Alison Venn · Menzies Institute for Medical Research5 papers (2016–2023)Jolieke C. van der Pols · University of Queensland5 papers (2016–2023)Peter R. Ebeling · Australian Regenerative Medicine Institute5 papers (2016–2023)Donald S.A. McLeod · QIMR Berghofer Medical Research Institute5 papers (2016–2023) · 5 papers (2016–2023)Rachel Ε. Neale · QIMR Berghofer Medical Research Institute5 papers (2016–2023) · 5 papers (2016–2023) · 5 papers (2016–2023)Penelope M. Webb · QIMR Berghofer Medical Research Institute5 papers (2016–2023)Günter Härtel · University of Queensland4 papers (2021–2023)David Sullivan · Royal Prince Alfred Hospital4 papers (2012–2014) · 4 papers (2021–2023)Alicia J. Jenkins · Baker Heart and Diabetes Institute4 papers (2012–2020)Russell Scott · University of Otago3 papers (2014–2020)M. Ng · The University of Sydney3 papers (2012–2014)Michael Friedländer · University of South Wales3 papers (2017–2019)Aimin Xu · University of Hong Kong2 papers (2012–2014)